公司发展战略目标

“华药韦德中心”通过2018年成功实施战略重组，引进股东作为战略投资方的优势资源，成功布局独具韦德中心特色和优势的长、中、短三个细分领域产品赛道：以TAF单方、复方及环孢素滴眼液为主体布局的韦德中心抗病毒领域和眼科领域“短赛道”；以肝素全产业链为主体布局的韦德中心抗凝领域“中赛道”；以注射用蜂毒为主体布局的韦德中心免疫制剂领域“长赛道”。通过起步、跨越、腾飞三个阶段实现“华药韦德中心”进入资本市场的战略目标! 

In 2018, NCPC Huakun successfully implemented strategy reorganization. Through the integration of the introduced strategic cooperative partners’ advantage of resources, NCPC Huakun layout of the unique long, medium, and short product track. “Short track” in the antiviral and ophthalmology field with Tenofovir alafenamide Fumarate Tablets、Emtricitabine and Tenofovir Alafenamide Fumarate Tablets、Ciclosporin Eye Drops; “Medium track” in the anticoagulation field with the entire heparin industrial chain; “Long track” in the field of immune with Bee Venom for Injection. To achieve NCPC Huakun's Strategic goal of entry the capital market through initial, climbing, and soaring stages.

           中国书法家协会会员刘熙墨手书        著名书法家甘路先生手书